Charles Schwab
KRYS icon

Charles Schwab’s Krystal Biotech KRYS Stock Holding History

Charles Schwab’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.7M Buy
254,828
+12,842
+5% +$3.84M 0.01% 819
2026
Q1 		$62.5M Sell
241,986
-788
-0.3% -$210K 0.01% 1005
2025
Q4 		$59.9M Sell
242,774
-89
-0% -$18.7K 0.01% 1037
2025
Q3 		$42.9M Sell
242,863
-3,317
-1% -$496K 0.01% 1258
2025
Q2 		$33.8M Sell
246,180
-4,334
-2% -$637K 0.01% 1347
2025
Q1 		$45.2M Buy
250,514
+7,344
+3% +$1.24M 0.01% 1141
2024
Q4 		$38.1M Buy
243,170
+2,954
+1% +$524K 0.01% 1321
2024
Q3 		$43.7M Buy
240,216
+19,777
+9% +$3.81M 0.01% 1210
2024
Q2 		$40.5M Buy
220,439
+31,536
+17% +$5.29M 0.01% 1215
2024
Q1 		$33.6M Buy
188,903
+3,865
+2% +$537K 0.01% 1283
2023
Q4 		$23M Buy
185,038
+5,258
+3% +$583K 0.01% 1506
2023
Q3 		$20.9M Buy
179,780
+17,614
+11% +$2.15M 0.01% 1486
2023
Q2 		$19M Buy
162,166
+2,277
+1% +$232K 0.01% 1539
2023
Q1 		$12.8M Sell
159,889
-726
-0.5% -$57K ﹤0.01% 1749
2022
Q4 		$12.7M Buy
160,615
+4,344
+3% +$322K ﹤0.01% 1722
2022
Q3 		$10.9M Buy
156,271
+7,519
+5% +$543K ﹤0.01% 1792
2022
Q2 		$9.77M Buy
148,752
+405
+0.3% +$25.2K ﹤0.01% 1842
2022
Q1 		$9.87M Buy
148,347
+8,729
+6% +$545K ﹤0.01% 1961
2021
Q4 		$9.77M Buy
139,618
+14,234
+11% +$829K ﹤0.01% 2017
2021
Q3 		$6.55M Buy
125,384
+3,312
+3% +$196K ﹤0.01% 2244
2021
Q2 		$8.3M Buy
122,072
+7,567
+7% +$528K ﹤0.01% 2094
2021
Q1 		$8.82M Buy
114,505
+15,326
+15% +$1.11M ﹤0.01% 2023
2020
Q4 		$5.95M Buy
99,179
+2,483
+3% +$124K ﹤0.01% 2135
2020
Q3 		$4.16M Buy
96,696
+20,148
+26% +$875K ﹤0.01% 2162
2020
Q2 		$3.17M Buy
76,548
+7,645
+11% +$368K ﹤0.01% 2250
2020
Q1 		$2.98M Buy
68,903
+1,539
+2% +$80.5K ﹤0.01% 2092
2019
Q4 		$3.73M Buy
67,364
+1,336
+2% +$65.5K ﹤0.01% 2177
2019
Q3 		$2.29M Buy
66,028
+45,189
+217% +$2.02M ﹤0.01% 2338
2019
Q2 		$840K Buy
+20,839
New +$681K ﹤0.01% 2631

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Charles Schwab's KRYS Position: Q2 2026 in Review

Charles Schwab increased its Krystal Biotech (KRYS) stake by 5.3% in Q2 2026, buying an estimated $3.84M and bringing the position to 254,828 shares worth $94.7M. The position accounts for 0.01% of the portfolio, ranked #819.

Charles Schwab first reported a position in KRYS in Q2 2019 and has held it in 29 quarters since. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Charles Schwab held 254,828 shares of Krystal Biotech worth $94.7M as of Q2 2026.
  • Charles Schwab bought 12,842 Krystal Biotech shares in Q2 2026, an estimated $3.84M.
  • Krystal Biotech made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #819 holding.
  • Charles Schwab first reported a position in Krystal Biotech in Q2 2019 and has held it in 29 quarters since.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.